Ken Griffin
NMRA icon

Ken Griffin’s Neumora Therapeutics NMRA Stock Holding History

Ken Griffin’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$80.7K Buy
41,400
+6,600
+19% +$17.1K ﹤0.01% 12167
2025
Q4 		$62.3K Sell
34,800
-66,500
-66% -$146K ﹤0.01% 11927
2025
Q3 		$184K Buy
101,300
+25,800
+34% +$41.7K ﹤0.01% 11342
2025
Q2 		$55.4K Sell
75,500
-51,600
-41% -$39.1K ﹤0.01% 11720
2025
Q1 		$127K Buy
127,100
+1,900
+2% +$3.25K ﹤0.01% 11125
2024
Q4 		$1.33M Buy
125,200
+121,300
+3,110% +$1.45M ﹤0.01% 6462
2024
Q3 		$51.5K Buy
3,900
+800
+26% +$9.33K ﹤0.01% 11873
2024
Q2 		$30.5K Sell
3,100
-1,400
-31% -$14.5K ﹤0.01% 12257
2024
Q1 		$61.9K Sell
4,500
-900
-17% -$14.6K ﹤0.01% 11963
2023
Q4 		$92.1K Buy
+5,400
New +$66.3K ﹤0.01% 11039

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

Ken Griffin's NMRA Position: Q1 2026 in Review

Ken Griffin reduced its Neumora Therapeutics (NMRA) stake by 32% in Q1 2026, selling an estimated $420K and leaving 343,586 shares worth $670K. The position accounts for ﹤0.01% of the portfolio, ranked #8591.

Ken Griffin first reported a position in NMRA in Q3 2023 and has held it in 9 quarters since. The position peaked at $30.3M in Q4 2023. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Ken Griffin held 343,586 shares of Neumora Therapeutics worth $670K as of Q1 2026.
  • Ken Griffin sold 162,217 Neumora Therapeutics shares in Q1 2026, an estimated $420K.
  • Neumora Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #8591 holding.
  • Ken Griffin first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 9 quarters since.
  • Ken Griffin's Neumora Therapeutics position peaked at $30.3M in Q4 2023.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.